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Abstract 
Drugs are a rare cause of pancreatitis. Whereas some drugs are well known to induce an 
attack of pancreatitis, some people may be more prone to develop pancreatitis because 
of personal susceptibility. We describe a recurrent case of acute pancreatitis after 
administration of several drugs in a patient with intestinal inflammatory bowel disease 
that needed to be treated with subsequent antiinflammatory agents. Genetic mutation in 
the CFTR gene was found in the patient that led us to postulate that CFTR was a trigger 
for drug-induced acute pancreatitis. In conclusion, genetic analysis should be advised in 
case of recurrent pancreatitis in patient with intestinal inflammatory bowel disease. 
Introduction 
Acute pancreatitis is an inflammatory process which occurs in a normal organ and 
which is diagnosed mainly by acute abdominal pain associated with a concomitant 
rise of serum amylase and lipase concentrations [1]. Once the diagnosis of acute 
pancreatitis is confirmed, the cause of the disease must be carefully examined. There 
is an extensive number of etiologies of acute pancreatitis and in 75–85% of patients the 
cause is easily identified. In western countries, gallstone migration along the common bile 
duct is the most frequent cause of acute pancreatitis before alcohol abuse [2, 3]. 
Hypertriglyceridemia, hypercalcemia, drugs and pancreatic cancer are other common 
causes of acute pancreatitis whereas other causes are uncommon, situational, or subject to 
ongoing controversy such as pancreas divisum or sphincter of Oddi dysfunction [3]. After 
a complete biological and clinical investigation, 20–30% of acute pancreatitis cases have 
no identifiable cause and those patients are often referred to as idiopathic pancreatitis [4]. 
However, this rate might decrease with recent advances in the understanding of the 
genetic or autoimmune mechanisms underlying acute pancreatitis. 
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Recently, mutations of the cationic trypsinogen gene (PRSS1), serine protease inhibitor 
Kazal type 1 (SPINK1) and cystic fibrosis transmembrane conductance regulator (CFTR) 
genes have been involved in idiopathic recurrent acute pancreatitis and chronic 
pancreatitis [5]. In pancreatic duct cells, the cystic fibrosis conductance regulator (CFTR) 
controls chloride and bicarbonate fluxes and consequently pancreatic fluid secretion. 
Since Sarles et al. [6] described acute pancreatitis with hyper-gamma-globulinemia in 
1965, pancreatitis has also been associated with Sjögren syndrome, primary sclerosing 
cholangitis, or primary biliary cirrhosis. 
We here report the case of a young male patient suffering from ulcerative colitis and 
presenting with recurrent acute episodes of pancreatitis, each of them strongly associated 
with the introduction of new antiulcerative colitis therapy. Although each episode of 
pancreatitis was drug-induced, we also found that pancreatitis was associated with a 
coincidental CFTR mutation that increases the likelihood of pancreatitis in the presence 
of additional deleterious factors. 
Case Report 
A 47-year-old man without any past medical history was diagnosed with ulcerative colitis based on 
endoscopy and colonic histology. Three weeks after mesalazine and prednisone therapy he presented a 
first episode of pancreatitis (fig. 1). There was no other medication, no alcohol or tobacco use and no 
familial history of pancreatic diseases. Calcium and serum triglyceride concentrations as well as liver 
enzymes were normal. Cholangio-MRI was normal. Mumps serology confirmed previous disease. Two 
weeks after mesalazine withdrawal, the patient presented a relapse of bloody diarrhea. A new 
colonoscopy was performed and confirmed a severe form of ulcerative colitis. Intravenous steroids and 
azathioprine were introduced, but 10 days after the patient presented a recurrent attack of pancreatitis. 
After 4 weeks of prednisone alone, weekly methotrexate injection was started but followed 3 months 
after by a third episode of pancreatitis. The absence of a known risk factor for chronic pancreatitis urged 
us to realize genetic testing. Genetic testing revealed the presence of the CFTR mutation, W1282X, that 
is known to increase the risk of chronic pancreatitis and idiopathic pancreatitis [7]. The stop of 
methotrexate was accompanied 3 weeks after by a relapse of colitis treated by infliximab. This treatment 
was followed by a fourth episode of pancreatitis 2 weeks after its introduction. 
Discussion 
The original feature of this case consists in recurrent pancreatitis occurring after the 
subsequent introduction of four dissimilar drugs used in ulcerative colitis. This case may 
provide a reasonable explanation for drug-induced pancreatitis. 
Personal history, clinical symptoms and laboratory tests may help identify the 
etiologies of acute pancreatitis, but 15–25% of cases remain of unknown origin. Drugs 
induce acute pancreatitis in 1.4–2% of cases [3]. A recent review classified ≥80 drugs in 
three categories according to the number of case reports published. Whereas no death has 
occurred with mesalazine, some have been reported with azathioprine. Azathioprine and 
mercaptopurine are associated with pancreatitis in 3–15% of patients that usually resolves 
upon drug cessation [3]. Methotrexate has been reported in two cases, one of them died. 
In the current case, the colitis severity required infliximab infusion, a compound also 
known to induce acute pancreatitis in rare cases. 
Recently, genetic mutations have been described in association with pancreatic 
diseases. CFTR mutations are involved in a variety of clinical conditions other than cystic 
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fibrosis, including chronic bronchitis as well as chronic and idiopathic pancreatitis. 
CFTR mutations may render some particular patients more susceptible to pancreatitis 
in the presence of other insults to the pancreas. Indeed, mutations in CFTR may disturb 
the subtle balance between proteases and their inhibitors by intrapancreatic acidification 
or by a defective apical trafficking of zymogen granules that might facilitate the 
intrapancreatic activation of digestive enzymes. Felley et al. [8] already reported that 
CFTR or SPINK-1 mutation increased the levels of serum pancreatic enzymes and the risk 
of pancreatitis in HIV patients. In the current case, the patient presented with one known 
mutation that is associated with an increased risk of pancreatic disease. 
In conclusion, we present for the first time a patient suffering from subclinical 
pancreatic disease that becomes active only when the pancreas is exposed to 
pancreatotoxic drugs. 
 
 
 
 
 
 
Fig. 1. Patient flowchart (not to scale): time course (horizontal thick arrow) of recurrent attacks of 
acute pancreatitis (AP) after the introduction of four dissimilar drugs aimed at treating ulcerative 
colitis. Recurrent bloody diarrhea followed each drug withdrawal (vertical arrows). Thin arrows 
indicate the start and end of each treatment. 
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